Oscotec Inc.

KOSDAQ:A039200 Stock Report

Market Cap: ₩936.0b

Oscotec Past Earnings Performance

Past criteria checks 0/6

Oscotec's earnings have been declining at an average annual rate of -8.4%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been declining at an average rate of 18.2% per year.

Key information

-8.4%

Earnings growth rate

-2.5%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate-18.2%
Return on equity-6.1%
Net Margin-15.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay For

Nov 20
With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay For

Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?

Aug 07
Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?

Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?

Apr 26
Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?

Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?

Feb 23
Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?

If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns

Jan 19
If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns

Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?

Dec 15
Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?

Revenue & Expenses Breakdown

How Oscotec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A039200 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2431,977-4,88213,10220,010
30 Jun 244,618-26,30511,63022,053
31 Mar 244,864-24,4459,19724,473
31 Dec 234,951-24,2808,46924,907
30 Sep 236,019-18,2157,86022,195
30 Jun 235,436-20,1667,01221,959
31 Mar 235,180-22,0476,87121,643
31 Dec 225,062-24,4306,21923,343
30 Sep 224,848-25,2135,56622,643
30 Jun 224,588-25,0625,47922,137
31 Mar 224,039-24,3715,21321,366
31 Dec 213,903-26,2635,54022,709
30 Sep 2128,955-17,7346,09834,754
30 Jun 2128,885-18,3025,90534,432
31 Mar 2143,415-7,4675,99735,724
31 Dec 2043,471-4,3575,70932,787
30 Sep 2018,182-15,5015,41122,352
30 Jun 2018,634-12,3465,57920,333
31 Mar 204,221-24,5848,05917,483
31 Dec 194,369-22,6017,91015,409
30 Sep 1918,885-4,9097,15211,579
30 Jun 1918,782-5,3936,50312,292
31 Mar 1918,657-2583,16710,171
31 Dec 1818,7033,3712,7066,970
30 Sep 183,917-8,4152,7507,191
30 Jun 183,809-5,5372,6854,457
31 Mar 183,721-5,3612,7144,205
31 Dec 173,908-5,8572,7934,821
30 Sep 174,600-7,4652,4308,437
30 Jun 174,343-7,0132,3047,735
31 Mar 173,968-9,4852,7156,795
31 Dec 163,554-8,8511,8236,547
30 Sep 166,816-5,2562,5921,823
30 Jun 1611,714-2,9853,4691,830
31 Mar 1614,8952593,8562,341
31 Dec 1518,3363955,0721,998
30 Sep 1517,441-1,0635,5392,159
30 Jun 1516,514-2,6155,5582,220
31 Mar 1516,745-2,5325,4682,247
31 Dec 1417,110-2,0225,5062,141
30 Sep 1416,982-4,6266,3812,309
30 Jun 1418,262-5,1566,9312,316
31 Mar 1420,467-4,8777,1382,284
31 Dec 1321,859-3,9717,1192,372

Quality Earnings: A039200 is currently unprofitable.

Growing Profit Margin: A039200 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A039200 is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare A039200's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A039200 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A039200 has a negative Return on Equity (-6.05%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oscotec Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Heeyoung LeeDaishin Securities Co. Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.
Sangsoo KimGoldman Sachs